- Home
- MED vs CRBP Comparison
MED vs CRBP Comparison
Compare MED & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- CRBP
- Stock Information
- Founded
- MED 1980
- CRBP 2009
- Country
- MED United States
- CRBP United States
- Employees
- MED N/A
- CRBP N/A
- Industry
- MED Packaged Foods
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- MED Consumer Staples
- CRBP Health Care
- Exchange
- MED Nasdaq
- CRBP Nasdaq
- Market Cap
- MED 213.6M
- CRBP 227.3M
- IPO Year
- MED N/A
- CRBP N/A
- Fundamental
- Price
- MED $18.27
- CRBP $16.73
- Analyst Decision
- MED Hold
- CRBP Strong Buy
- Analyst Count
- MED 1
- CRBP 7
- Target Price
- MED $17.00
- CRBP $65.86
- AVG Volume (30 Days)
- MED 202.4K
- CRBP 346.4K
- Earning Date
- MED 11-04-2024
- CRBP 11-07-2024
- Dividend Yield
- MED 36.09%
- CRBP N/A
- EPS Growth
- MED N/A
- CRBP N/A
- EPS
- MED 0.67
- CRBP N/A
- Revenue
- MED $674,475,000.00
- CRBP N/A
- Revenue This Year
- MED N/A
- CRBP N/A
- Revenue Next Year
- MED N/A
- CRBP N/A
- P/E Ratio
- MED $27.44
- CRBP N/A
- Revenue Growth
- MED N/A
- CRBP N/A
- 52 Week Low
- MED $17.07
- CRBP $4.00
- 52 Week High
- MED $76.42
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- MED 47.86
- CRBP 37.25
- Support Level
- MED $17.07
- CRBP $15.65
- Resistance Level
- MED $19.96
- CRBP $17.18
- Average True Range (ATR)
- MED 0.94
- CRBP 1.26
- MACD
- MED -0.14
- CRBP 0.35
- Stochastic Oscillator
- MED 29.93
- CRBP 21.09
About MED MEDIFAST INC
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.